Revenue
2012
2013
2014
2015
2016
2022
2023
2024
2025
Eledon Pharmaceuticals, Inc. (ELDN)
Price$3.02Cached quote
Net income
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2012
2013
2014
2015
2016
Total cash / debt
CashTotal debt
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 |
| Research & development | $66.3M | $52.0M | $30.3M | $27.1M | $23.7M | $6.1M | $8.1M | $6.8M | $2.0M | $3.2M | $32.6M | $14.6M | $12.2M | $7.4M |
| Operating expenses | $83.3M | $70.6M | $43.0M | $88.4M | $36.9M | $18.5M | $16.1M | $14.1M | $13.1M | $5.1M | $45.3M | $23.5M | $15.7M | $9.6M |
| Operating income | −$83.3M | −$70.6M | −$43.0M | −$88.4M | −$36.9M | −$18.5M | −$16.1M | −$14.1M | −$13.1M | −$5.1M | −$45.3M | −$23.5M | −$15.7M | −$9.6M |
| EBITDA | −$82.9M | −$70.2M | −$42.6M | −$39.4M | — | −$18.5M | −$16.0M | −$14.0M | −$13.1M | −$5.1M | −$45.2M | −$23.4M | −$15.7M | −$9.6M |
| Net income | −$45.6M | −$36.2M | −$116.5M | −$88.0M | −$34.5M | −$22.8M | −$16.0M | −$14.1M | −$13.1M | −$5.7M | −$45.1M | −$23.3M | −$15.7M | −$9.6M |
| Basic EPSper basic share | -$0.52 | -$0.66 | -$4.73 | -$6.16 | -$2.33 | -$15.72 | -$24.42 | -$28.08 | -$41.40 | -$44.28 | -$325.62 | -$583.20 | -$6,159.25 | -$5,036.59 |
| Diluted EPSper diluted share | -$0.52 | -$0.66 | -$4.73 | -$6.16 | -$2.33 | -$15.72 | -$24.42 | -$28.08 | -$41.40 | -$44.28 | -$325.62 | -$583.20 | -$6,159.25 | -$5,036.59 |
Owners
Reported shareholders
7.78%of listed shares
BVF INC/IL6.29M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BVF INC/IL | 7.78%6.29M shares |
BlackRock, Inc. | 6.33%5.12M shares |
Defilade Capital Management, L.P. | 4.36%3.53M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.22%3.42M shares |
GOLDMAN SACHS GROUP INC | 3.10%2.51M shares |
Ensign Peak Advisors, Inc | 2.60%2.1M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.42%1.96M shares |
Catalio Capital Management, LP | 2.10%1.7M shares |
STATE STREET CORP | 2.01%1.62M shares |
Zimmer Partners, LP | 1.97%1.6M shares |
SPHERA FUNDS MANAGEMENT LTD. | 1.47%1.19M shares |
AWM Investment Company, Inc. | 1.36%1.1M shares |
UBS Group AG | 1.30%1.05M shares |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 1.28%1.04M shares |
MILLENNIUM MANAGEMENT LLC | 1.21%979.71K shares |
BANK OF AMERICA CORP /DE/ | 1.09%883.1K shares |
ADAR1 Capital Management, LLC | 0.80%647.81K shares |
22NW, LP | 0.79%636.36K shares |
NORTHERN TRUST CORP | 0.76%616.4K shares |
AQR CAPITAL MANAGEMENT LLC | 0.72%581.03K shares |
Percentages use 80.89M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Oct 29, 2024Form 4 | BIOTECHNOLOGY VALUE FUND II LP +9Other | BuyPre-funded Warrants to Purchase Common Stock · derivative | 440.5K | $3.65 | $1.61M | 838.5K |
| Oct 29, 2024Form 4 | BIOTECHNOLOGY VALUE FUND II LP +9Other | BuyPre-funded Warrants to Purchase Common Stock · derivative | 2.10M | $3.65 | $7.67M | 6.24M |
| Oct 29, 2024Form 4 | BIOTECHNOLOGY VALUE FUND II LP +9Other | BuyPre-funded Warrants to Purchase Common Stock · derivative | 2.21M | $3.65 | $8.08M | 7.42M |